Clinical trial Recruiting at 1 site Interventional Ages 18 to 45

Liquid-phase concentrated growth factor versus arthrocentesis for temporomandibular disc displacement

Official title: Injection of Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Management of Temporomandibular Disc Displacement: A Randomized Controlled Clinical Trial

Run by Horus University · NCT07075276 · Data updated 2026-11-12

This trial will test whether injecting liquid-phase concentrated growth factor into the temporomandibular joint works better than standard arthrocentesis for adults (18–45) with unilateral disc displacement.

Quick facts

Study typeInterventional
Ages18 Years to 45 Years
SexAll
Enrollment32 (estimated)
SponsorHorus University
Academic / other
Locations1 site (Damietta, New Damietta)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedNovember 1, 2026
Study endsDecember 1, 2026
Registry record updatedAugust 17, 2026
Trial IDNCT07075276 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–45 years old with unilateral TMJ disc displacement (per RDC/TMD), ASA I status, near-complete natural dentition with Angle Class I occlusion, no prior TMJ surgery, and symptoms such as pain, joint sounds, or limited mouth opening.

Probably not a fit

Patients with mechanical TMJ deformities, uncontrolled systemic or autoimmune diseases, relevant psychiatric conditions, prior TMJ surgery, or those outside the 18–45 age range are unlikely to qualify or benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized clinical trial compares liquid-phase concentrated growth factor (LPCGF) injections with conventional arthrocentesis in adults aged 18–45 diagnosed with unilateral temporomandibular disc displacement. Eligible participants are ASA I with near-complete natural dentition and Angle Class I occlusion, and will be randomized to receive either LPCGF or standard arthrocentesis with standardized follow-up visits. Outcomes include pain, joint sounds, maximum mouth opening, and safety measures to determine whether LPCGF provides superior symptom relief or functional improvement. The study is conducted at the Faculty of Dentistry, Horus University in Damietta/New Damietta, Egypt, and excludes patients with prior TMJ surgery or systemic conditions that impair healing.

Why it matters

Potential benefit: If successful, LPCGF could provide better or longer-lasting pain relief and improved jaw opening compared with conventional arthrocentesis.

How similar studies have gone: Other autologous growth-factor therapies (for example PRP or other concentrated growth factors) have shown promising but mixed results in TMJ disorders, so LPCGF represents a relatively novel but plausible approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\. Adults aged 18-45 years. 2. Patients scored as (ASA I).9 3. Presence of complete or nearly complete set of natural dentition with Angle class I occlusion. 4. Diagnosed with unilateral involvement of disc displacement, according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).10 5. Symptoms include one or more of the following: pain, joint sounds, and limited mandibular movement (Maximum Mouth Opening\< 40mm) 6. No prior surgical intervention for TMD. 7. Patient's willingness to participate and follow the study protocol.

Exclusion Criteria:

* 1\. TMJ pathology related to mechanical deformities 2. Psychiatric problems or presence of systemic diseases that may affect healing (e.g., uncontrolled diabetes, autoimmune disorders, hematologic or neurologic disorders, inflammatory or connective tissue disorders as well as rheumatological or previous infectious diseases, head and neck cancer). 3. Patient unwilling or has contraindication to MRI 4. Previous injections or surgical interventions of the TMJ. 5. Concurrent use of anticoagulants or anti-inflammatory medications within the last 30 days. 6. Pregnant or breastfeeding women. 7. History of trauma or infection in the TMJ region. 8. Allergy to local anesthetics or other components used in the study. 9. Patients diagnosed with (Disc Displacement with reduction with no pain or limited mandibular movements).

Where it's running

  • Faculty of Dentistry- Horus University in Egypt
    Damietta, New Damietta, Egypt
    Recruiting

Study contacts

  • Principal investigator: Mohamed Ali Habib, Teaching Assistant — Horus University in Egypt - Faculty of dentistry
  • Study coordinator: Mohamed Ali Habib, Teaching assistant
  • Email: mbasiouny@horus.edu.eg
  • Phone: +2001069505336

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.